Tiantu Capital
天图投资
Tiantu Capital is a Chinese venture capital firm with a notable track record in consumer and healthcare investments. It led the Series A and A+ rounds in premium coffee brand Saturnbird in 2019, as reported by FreeS Fund , and has been an active backer of biotech companies through multiple deals including leading the angel round of LaiMang Bio in early 2022 and following on in its 2024 raise . The firm also led rounds in PAM2L Biotechnologies and Xunweishi, and has continued to support portfolio companies like Signet Therapeutics alongside Yunmu Capital and others . Its investment in ReviR Therapeutics was part of a $30 million Series A syndicate in mid-2024 that included 5Y Capital, DH Capital, and others .
AI-generated — may contain errors, please verify.
Coverage
Summer rains bring gentle relief, good things flourish like green grass | Z News
Long, languid July.
5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
5Y News | 5Y Capital Portfolio Company "Laimang Biotech" Raises 50 Million Yuan in New Funding
Accelerating the clinical translation of ultra-low-dose CAR-T.
The Day Munger Died: 18 WeChat Moments About Him
Mourning the Passing of a Wise Mind
Two Decades of RMB Funds: Between Life and Death
Are USD Funds in Trouble? Is It the RMB Funds' Turn to Make a Move?
June, Vitality | 5Y News Monthly
The big news from last month.
5Y News | PAM2L Biotechnologies Closes Tens of Millions of RMB in Angel+ Round
Opening a new paradigm in synthetic biomaterials R&D.
February: When the Tiger Roars, the Wind Rises | 5Y News Monthly
The big news from last month.
5Y News | Limmuno Biotech Closes Nearly RMB 100 Million Angel Round
Immunometabolic Reprogramming + AI-Powered Computation for Innovative Cancer Immunotherapy
5Y News | AI+RNA Startup ReviR Therapeutics Closes Tens of Millions of Dollars in Pre-A Round
Using AI algorithms and gene technology to drive targeted RNA drug development.
November: Foresight and Boundless Imagination | 5Y News Monthly
The big news from last month.
5Y News | Signet Therapeutics Raises Nearly $10 Million to Power AI-Enabled Innovative Targeted Drug Development Through Disease Modeling Platform
Advancing pharmaceutical innovation in China.
Efficacy skincare brand "Shiyan" has raised nearly 100 million RMB in a Series A round led by Gaorong Ventures.
Focusing on novel process innovation to create products that actually deliver results.
Xunweishi raises tens of millions of yuan in angel round co-led by Source Code Capital
Put consumer needs first, and elevate happiness and satisfaction.
FreeS Family Funding News · June | Saturnbird, Shize Biotech, and Light Travel Secure Funding
We also released two short videos this week — follow us to check them out.
'Clean Beauty' Pioneer Brand 'Lan' Announces New Funding Round Led by Source Code Capital
It was the first to propose the "nourish skin with oil" concept, and at one point broke into Tmall's top 10 serum category rankings.
"Saturnbird" Closes Tens of Millions of RMB in Series A and A+ Rounds, FreeS Fund Continues to Follow On | FreeS Fund News
The first domestic brand to top Tmall's Double 11 coffee rankings
Since China will give birth to far more world-class brands than we can imagine over the next 20 years, what can we do right now?
Study the essence of industries, capture signals of the future.
The World Is Out There, and We Have to Go | 8 Young FreeS Fund Entrepreneurs Named to Forbes China "30 Under 30" List
Meet youth. Meet innovation and the extraordinary.
